AUTHORS
Joseph Mort, MD, B. Douglas Smith, MD2, Ivana Gojo, MD3, Jonathan Allen Webster, MD4, Amy DeZern, MD, MHS5, Gabrielle T. Prince, MD6, Tania Jain, MBBS7, Javier Bolanos-Meade, MD8, Lukasz P. Gondek, MD, PhD9, Gabriel Ghiaur, MD, PhD10, William Brian Dalton, MD, PhD11, Theodoros Karantanos, MD, PhD12, Suman Paul, PhD, MBBS13, Ephraim Fuchs, MD14, Jorge Florindez, MD15, Cole H Sterling, MD16, Richard Ambinder, MD, PhD17, Christian Burris Gocke, MD, PhD18, Philip Imus, MD19, Syed Abbas Ali, MBBS20, Carol Huff, MD21, Richard John Jones, MD22, Mark J. Levis I, MD PhD23, Alexander Joseph Ambinder, MD, MPH24
AFFILIATIONS
1 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
2 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
3 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
4 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
5 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
6 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
7 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
8 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
9 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
10 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
11 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
12 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
13 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
14 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
15 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
16 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
17 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
18 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
19 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
20 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
21 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
22 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
23 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
24 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
ABSTRACT
Background: Post-transplant gilteritinib reduces relapse in FLT3-ITD acute myeloid leukemia (AML) with measurable residual disease (MRD), but maintenance may be delayed or omitted after complications such as graft-versus-host disease (GVHD). Because graft source strongly influences GVHD, it may affect both post-transplant outcomes and whether patients can initiate maintenance. In the randomized BMT-CTN 1506/MORPHO trial, patients were randomized only after post-transplant screening, so those with prohibitive early complications never entered the randomized population; the trial therefore was unable to address whether graft source affects the ability to reach maintenance. We retrospectively analyzed a single-center cohort to examine the impact of graft source on GVHD-free, relapse-free survival (GRFS), GVHD, and the ability to initiate gilteritinib maintenance.
Methods: Patients with FLT3-ITD AML in complete remission receiving reduced-intensity conditioning allogeneic hematopoietic cell transplantation (alloHCT) with post-transplant cyclophosphamide at Johns Hopkins (2016-2024) were retrospectively analyzed by graft source. At Johns Hopkins, BM grafts are preferred unless the donor is unrelated or MRD is detected by multiparametric flow cytometry on pre-transplant evaluation. The primary endpoint was initiation of post-transplant gilteritinib, and reasons for non-initiation. Secondary endpoints included GRFS, acute GVHD, chronic GVHD, OS, and RFS. Survival outcomes were estimated using Kaplan-Meier methods, and cumulative incidence was assessed via competing-risk analysis.
Results: At Johns Hopkins (2016-2024), 52 patients (50%) received bone marrow (BM) grafts and 53 (50%) received peripheral blood stem cell (PBSC) grafts. More patients receiving BM grafts had NPM1 co-mutations (75% vs 57%). BM graft source was associated with improved GRFS (71% vs 50% at 1 year, P=0.013; HR 1.87 [1.04-3.34] after adjustment for NPM1 status, P=0.036). FLT3-ITD MRD testing was performed in 46% of patients pre-transplant and 48% post-transplant. Among tested patients, more PBSC recipients had detectable FLT3-ITD MRD both before transplant (50% vs 33%) and after transplant (10% vs 0%). Despite this greater residual disease burden in PBSC graft recipients, more BM graft recipients initiated post-transplant gilteritinib (89% vs 65%, P=0.006). PBSC grafts were associated with a trend toward increased GVHD (day +180 grade II-IV acute GVHD, 42% vs 25%, P=0.085; 1-year any-grade chronic GVHD, 25% vs 9.6%, P=0.063). Among patients for whom maintenance was indicated but not started (5 BM and 13 PBSC recipients), GVHD was the barrier in 1 BM patient (20%) vs 8 PBSC (62%) recipients. When comparing patients who received BM to PBSC grafts, there was no difference in overall survival (81% vs 66% at 2 years, P=0.2), relapse-free survival (75% vs 65% at 2 years, P=0.2), or relapse (19% vs 18% at 2 years, P=0.8) by graft source received. A trend toward lower non-relapse mortality with BM grafts was observed (6% vs 18% at 2 years, P=0.063).
Conclusions: In this single-center cohort study of patients with FLT3-ITD AML undergoing alloHCT, BM grafts were associated with improved GRFS. PBSC recipients were less likely to initiate gilteritinib despite having a higher rate of MRD-positive disease. Acute GVHD was the most common barrier to initiation of gilteritinib in patients for whom it was indicated, and it was a more common barrier in patients receiving PBSC than in BM. These retrospective, hypothesis-generating findings suggest that the choice of graft-source may shape post-transplant outcomes not only by impacting rates of GVHD, but also by influencing the downstream ability to deliver maintenance therapy.
DISCLOSURES
Joseph Mort, MD: No relevant conflicts of interest to declare.